2 results
P
Patients with myeloproliferative neoplasms (MPNs)
I/C
Antithrombotic therapy and/or cytoreduction, No randomized trials were identified. Ten observational studies involving 1295 patients with MPN were included in the analysis.
O
Recurrent thrombosis, Arterial or recurrent venous thrombotic event on follow-up
P
OSMF patients
I/C
medical interventions, placebo
O
mouth opening, burning sensation, cheek flexibility